CC
Commodore Capital Portfolio holdings
AUM
$1.5B
1-Year Est. Return
149.78%
This Fund
S&P 500
1 Year Est. Return
+149.78%
AUM
$1.5B
AUM Growth
-$546M
(-27%)
Holding
43
Top Buys
| 1 | +$23M | |
| 2 | +$22M | |
| 3 | +$21.4M | |
| 4 |
Alkermes
ALKS
|
+$13.6M |
| 5 |
Replimune Group
REPL
|
+$12.1M |
Top Sells
| 1 | +$332M | |
| 2 | +$142M | |
| 3 | +$97.6M | |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$93.9M |
| 5 |
Nuvalent
NUVL
|
+$83.8M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Relay Therapeutics
RLAY
$1.89B
| $144M | 9.57% |
17,000,000
|
|
||
|
2
Alkermes
ALKS
$4.61B
| $99.3M | 6.61% |
3,550,000
+453,246
|
|
||
3
Tyra Biosciences
TYRA
$1.94B
| $88.7M | 5.91% |
3,375,000
|
|
||
4
Xenon Pharmaceuticals
XENE
$4.82B
| $80.7M | 5.37% |
1,800,000
-900,000
|
|
||
5
Spyre Therapeutics
SYRE
$3.17B
| $78.2M | 5.21% |
2,388,245
+400,161
|
|
||
6
Cogent Biosciences
COGT
$5.73B
| $78M | 5.19% |
2,196,845
-5,053,155
|
|
||
7
Enliven Therapeutics
ELVN
$1.72B
| $72.3M | 4.81% |
4,692,809
|
|
||
8
Celldex Therapeutics
CLDX
$1.99B
| $69.7M | 4.64% |
2,565,000
-463,335
|
|
||
9
Amylyx Pharmaceuticals
AMLX
$1.58B
| $68.3M | 4.54% |
5,650,000
+1,574,522
|
|
||
10
Terns Pharmaceuticals
TERN
$4.81B
| $59.6M | 3.97% |
1,475,000
-4,225,000
|
|
||
11
Kymera Therapeutics
KYMR
$6.33B
| $58.4M | 3.88% |
750,000
|
|
||
12
Soleno Therapeutics
SLNO
$1.9B
| $55.6M | 3.7% |
1,200,000
-150,000
|
|
||
|
13
Nuvalent
NUVL
$7.7B
| $55.3M | 3.68% |
550,000
-850,000
|
|
||
|
ORKA
14
Oruka Therapeutics
ORKA
$1.55B
| $53.1M | 3.54% |
1,753,054
|
|
||
15
Pharvaris
PHVS
$1.71B
| $52.4M | 3.49% |
1,889,445
-529,031
|
|
||
16
Nurix Therapeutics
NRIX
$1.61B
| $43.2M | 2.87% |
2,275,000
-1,505,055
|
|
||
17
Protagonist Therapeutics
PTGX
$6.09B
| $39.3M | 2.62% |
450,000
-575,000
|
|
||
18
Assembly Biosciences
ASMB
$448M
| $34M | 2.26% |
1,000,000
|
|
||
|
LBRX
19
LB Pharmaceuticals
LBRX
$631M
| $33.4M | 2.22% |
1,500,000
|
|
||
20
CytomX Therapeutics
CTMX
$825M
| $32.8M | 2.18% |
7,692,300
|
|
||
21
Alto Neuroscience
ANRO
$691M
| $32.5M | 2.16% |
+1,823,196
|
|
||
22
Palisade Bio
PALI
$303M
| $26.9M | 1.79% |
+11,445,000
|
|
||
|
DFTX
23
Definium Therapeutics
DFTX
$1.79B
| $26.8M | 1.78% |
2,000,000
-1,225,000
|
|
||
|
CNTA
24
Centessa Pharmaceuticals
CNTA
$4.02B
| $25M | 1.66% |
1,000,000
-1,850,000
|
|
||
25
PepGen
PEPG
$425M
| $22.1M | 1.47% |
3,400,000
+1,042,681
|
|